Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.79% $1.270
America/New_York / 28 mar 2024 @ 12:37
FUNDAMENTALS | |
---|---|
MarketCap: | 56.97 mill |
EPS: | 0.270 |
P/E: | 4.70 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 44.86 mill |
Avg Daily Volume: | 0.318 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 4.70 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.80x |
Company: PE 4.70 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.19 (72.12%) $0.916 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.206 - 1.334 ( +/- 5.04%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Golipour Azadeh | Sell | 37 334 | Restricted Stock Unit |
2024-02-01 | Golipour Azadeh | Buy | 37 334 | Common Stock |
2024-02-05 | Golipour Azadeh | Sell | 12 232 | Common Stock |
2024-02-01 | Ridha Essra | Sell | 32 834 | Restricted Stock Unit |
2024-02-01 | Ridha Essra | Buy | 32 834 | Common Stock |
INSIDER POWER |
---|
54.90 |
Last 100 transactions |
Buy: 6 327 240 | Sell: 1 294 974 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.270 (0.79% ) |
Volume | 0.0208 mill |
Avg. Vol. | 0.318 mill |
% of Avg. Vol | 6.53 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.